Mangalam Drugs locked lower circuit for 10 straight trading sessions

In past two-weeks, the stock tanked 40% to Rs 265 from its 52-week high of Rs 442 touched on December 8.

Mangalam Drugs down 5% for 10 straight trading sessions
SI Reporter Mumbai
Last Updated : Dec 22 2015 | 3:18 PM IST
Shares of Mangalam Drugs & Organics have locked in lower circuit for the 10 straight trading sessions, down 5% at Rs 265 on the BSE.

In past two-weeks, the stock of pharmaceutical company tanked 40% from its 52-week high of Rs 442 touched on December 8.

Till 11:52 a.m. a combined 417,700 equity shares changed hands and there were pending sell orders for 142,975 shares on the BSE and NSE.

According to disclosure filed by the company, the promoters had sold nearly two lakh shares worth of Rs 6 crore through open market during last week.

Shree Rasbihari Trading & Investment Pvt Ltd and Chandrakanta Murlidhar Dhoot had disposed 173,896 shares amounting of Rs 5.71 crore of Mangalam Drugs between December 16 and 17, the BSE data shows.

On November 16, 2015, the company’s board had allotted 1.2 million equity shares on conversion of 1.2 million share warrants of Rs 10 each at a premium of Rs 55 per share out of the total 2.65 million warrants allotted to promoter group on preferential basis.

Meanwhile, before stock starts downfall, the market value of the company surged 22 times or 2,110% from Rs 20.05 to Rs 442.

Ipca Laboratories, which held 10.58% stake in Mangalam Drugs at the beginning of the current calendar year, had sold its entire holding in the company during first half of 2015, the shareholding pattern data shows. Since June 2015, the stock rallied 780% from Rs 58.
 

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Dec 22 2015 | 11:53 AM IST

Next Story